Inactive Instrument

Vitrolife AB Share Price Nasdaq Stockholm

Equities

SE0000816043

Medical Equipment, Supplies & Distribution

Financials

Sales 2024 * 3.6B 331M 26.45B Sales 2025 * 3.98B 366M 29.21B Capitalization 22.42B 2.06B 165B
Net income 2024 * 530M 48.75M 3.89B Net income 2025 * 677M 62.27M 4.97B EV / Sales 2024 * 6.39 x
Net Debt 2024 * 600M 55.19M 4.41B Net cash position 2025 * 103M 9.5M 759M EV / Sales 2025 * 5.61 x
P/E ratio 2024 *
42.5 x
P/E ratio 2025 *
33.3 x
Employees -
Yield 2024 *
0.81%
Yield 2025 *
0.83%
Free-Float 55.39%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 31/07/23
Director of Finance/CFO 54 31/12/21
Chairman 68 06/05/15
Members of the board TitleAgeSince
Director/Board Member 53 01/05/19
Chairman 68 06/05/15
Director/Board Member 64 26/04/18
More insiders
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
More about the company